Valuation: GSK plc

Capitalization 73.57B 100B 85.2B 78.03B 137B 9,566B 138B 925B 361B 4,556B 377B 369B 15,766B P/E ratio 2026 *
11.5x
P/E ratio 2027 * 10.8x
Enterprise value 85.95B 117B 99.54B 91.16B 160B 11,176B 162B 1,081B 422B 5,323B 440B 431B 18,419B EV / Sales 2026 *
2.55x
EV / Sales 2027 * 2.35x
Free-Float
92.31%
Yield 2026 *
3.79%
Yield 2027 * 3.97%
1 day+0.15%
1 week-0.67%
Current month-4.36%
1 month-15.00%
3 months-14.21%
6 months+1.10%
Current year+1.10%
1 week 1,831.5
Extreme 1831.5
1,896.5
1 month 1,831.5
Extreme 1831.5
2,202
Current year 1,774
Extreme 1774
2,282
1 year 1,288.6
Extreme 1288.6047
2,282
3 years 1,242.5
Extreme 1242.5
2,282
5 years 1,242.5
Extreme 1242.5
3,408.16
10 years 1,242.5
Extreme 1242.5
3,408.16
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Director/Board Member 66 01/05/2020
Change 5d. change 1-year change 3-years change Capi.($)
+0.08%-0.67%+31.80%+27.66% 100B
+1.88%+0.15%+28.30%+122.56% 846B
-0.10%-1.13%+43.81%+37.69% 533B
+0.82%-2.18%+7.13%+38.90% 356B
+1.21%-0.97%+22.40%+12.53% 324B
+1.18%+1.29%+31.44%+13.23% 282B
+0.30%-0.12%+24.02%+22.81% 278B
+0.66%-0.50%+39.92%-4.26% 275B
+3.34%+6.03%-32.03%-48.08% 203B
-0.95%+1.69%+19.86%+41.77% 179B
Average +0.90%-0.91%+21.66%+26.48% 337.56B
Weighted average by Cap. +1.03%-1.22%+24.84%+44.75%

Financials

2026 *2027 *
Net sales 33.77B 46.09B 39.11B 35.82B 62.99B 4,391B 63.5B 425B 166B 2,091B 173B 169B 7,237B 35.39B 48.3B 40.98B 37.53B 66.01B 4,601B 66.54B 445B 174B 2,191B 181B 177B 7,584B
Net income 6.35B 8.67B 7.36B 6.74B 11.85B 826B 11.95B 79.91B 31.19B 393B 32.53B 31.85B 1,361B 6.72B 9.17B 7.78B 7.13B 12.53B 874B 12.63B 84.5B 32.98B 416B 34.4B 33.68B 1,440B
Net Debt 12.38B 16.9B 14.34B 13.13B 23.1B 1,610B 23.28B 156B 60.79B 767B 63.41B 62.08B 2,654B 9.49B 12.95B 10.99B 10.06B 17.7B 1,234B 17.84B 119B 46.58B 588B 48.58B 47.56B 2,033B
Logo GSK plc
GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
Employees
66,841
Date Price Change Volume
11/05/26 1,844.50 p +0.08% 5,176,377
08/05/26 1,843.00 p -0.83% 6,109,465
07/05/26 1,858.50 p -0.88% 14,943,290
06/05/26 1,875.00 p +0.97% 8,582,557
05/05/26 1,857.00 p -2.31% 7,779,937
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
18.43GBP
Average target price
20.30GBP
Spread / Average Target
+10.15%

Quarterly revenue - Rate of surprise